Drug intelligence / Profile preview

RGI-AB-03

Development stage: Preclinical
Lead developer: REGiMMUNE
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

RGI-AB-03 is a monoclonal antibody currently in preclinical development by REGiMMUNE for the treatment of solid tumors. As part of REGiMMUNE's oncology pipeline, the candidate is being investigated for its potential therapeutic efficacy against various malignancies. While the specific molecular target and mechanism of action have not been publicly disclosed by the developer, the drug represents one of several antibody-based programs (including RGI-AB-01 and RGI-AB-02) aimed at addressing unmet needs in the oncology space. The program is currently in the early research and preclinical stages.

Beyond the preview

Go deeper on RGI-AB-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGI-AB-03.

Explore the full profile